Objective: Evaluate the association between SARS-CoV-2 serologic status in immunologically naïve patients and risk of preeclampsia at time of delivery.
Study design: We conducted a retrospective cohort study of pregnant patients admitted to our institution from August 1st to September 30th, 2020. We recorded maternal medical and obstetric characteristics, and SARS-CoV-2 serologic status. Our primary outcome was the incidence of preeclampsia. Antibody testing was performed and patients were classified into seropositive groups: IgG+, IgM+, or both IgG+ and IgM+. Bivariate and multivariable analyses were performed.
Results: We included 275 patients that were negative for SARS-CoV-2 antibodies, and 165 that were positive. Seropositivity was not associated with higher rates of preeclampsia (p=0.183), or with preeclampsia with severe features (p=0.916) even after adjusting for maternal age> 35, BMI≥ 30, nulliparity, and previous history of preeclampsia, and type of serologic status. Previous preeclampsia had the greatest association with development of preeclampsia (OR=13.40 95% CI [4.98-36.09]; p< 0.05), and with preeclampsia with severe features (OR=5.46 95% CI [1.65-18.02]; p< 0.05).
Conclusions: We found that in an obstetric population there was no association between SARS-CoV-2 antibody status and the risk of preeclampsia.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.